|
|
|
| A study on the association of baseline CD4+T and early antiretroviral therapy effect among MSM HIV/AIDS patients |
| ZHENG Jin-lei,PAN Xiao-hong,MA Qiao-qin,CHEN Jun-fang,YANG Jie-zhe,HE Lin,XU Yun,JIANG Jun,CHEN Wan-jun,LUO Yan,ZHANG Xing-liang,XI Sheng-jun
|
| Zhejiang Provincial Center for Disease Control and Prevention,Zhejiang,Hangzhou,310051,China |
|
|
|
|
Abstract Objective To analyze the association between baseline level of CD4+T and the therapeutic effects of highly active antiretroviral therapy （HAART） for MSM HIV/AIDS in Hangzhou City. Methods We recruited MSM HIV/AIDS who initiated HAART from July 1st 2014 to June 30th 2016 into the study in Hangzhou City. MSM HAART patients whose baseline CD4+T≥500 copies/μL was set as observation group,and baseline CD4+T<500 copies/μL was set as control group. Patients were tested CD4 count and viral load regularly. We compared HAART effects of observation group and control group. Results We recruited 1 206 MSM patients with access to HAART in our study in Hangzhou City. And 1 026 patients were set in control group,and 180 patients were set in observation group. In the 12th month,the rates of two groups' patients with CD4 successfully recovered （reached 719 cells/μL）were 12.50% and 39.13%. In the 18th month,the rates were 13.75% and 38.71%. The median time of patients with CD4 first successfully recovered to 719 cells/μL was 7.2 months in observation group,while the median time of control group was 20.4 months,which was longer than observation group（P<0.05）. A total of 375 patients were tested viral load,and the successful suppression rate of viral load was 97.33%. The rates of observation and control group were 96.34% and 97.50%（P>0.05）. Conclusion The rates of viral successful suppression were similar between baseline CD4 counts ≥500 cells/μL group and<500 cells/μL group among MSM HAART patients. Recovery time in baseline CD4 counts ≥500 cells/μL group was shorter than baseline CD4 counts<500 cells/μL group.
|
|
Published: 07 December 2017
|
|
|
|
|
|
[1] 徐云,潘晓红,杨介者,等.浙江省2004—2013年MSM的艾滋病疫情分析[J]. 中国艾滋病性病,2015,21（1）:37- 40.
[2] 中华人民共和国国家卫生与计划生育委员会. 国家卫生计生委办公厅关于修订艾滋病患者免费抗病毒治疗标准的通知（国卫办医函〔2014〕326号）[EB/OL].[2017-09-06].
http://www.nhfpc.gov.cn/yzygj/s3593/201405/95edf9ac8abb4e1a 9f3482501b0ae4be.shtml.
[3] 郑锦雷,杨介者,徐云,等. 高效抗逆转录病毒治疗艾滋病方案的效果评价[J]. 浙江预防医学,2010,22（1）:5-7.
[4] The INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection[J]. N Engl J Med,2015,373（9）:795-807.
[5] 郭志宏,姚亚萍,李西婷,等. 浙江地区健康青少年和成人外周血T淋巴细胞免疫表型调查及正常参考值范围的建立[J]. 中国预防医学杂志,2008,9（1）:32-35.
[6] 中华人民共和国卫生部艾滋病临床专家工作组.《国家免费艾滋病抗病毒药物治疗手册》[M].4版.北京:人民卫生出版社,2016.
[7] 郑锦雷,徐云,何林,等.浙江省2009—2014年艾滋病抗病毒治疗效果分析[J].中华流行病学杂志,2016,37（5）:673-677.
[8] HEYMER K J,WILSON D P. Treatment for prevention of HIV transmission in a localised epidemic:the case for South Australia[J]. Sex Health,2011,8（3）:280-294.
[9] SOOD N,WAGNER Z,JAYCOCKS A,et al. Test-and-treat in Los Angeles:a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County[J]. Clin Infect Dis,2013,56（12）:1789-1796.
[10]SABIN C A,COOPER D A,COLLINS S,et al. Rating evidence in treatment guidelines:a case example of when to initiate combination antiretroviral therapy （cART） in HIV-positive asymptomatic persons[J]. AIDS,2013,27（12）: 1839-1846.
[11]SUN J J,LIU L,SHEN J Y,et al. Trends in baseline CD4 cell counts and risk factors for late antiretroviral therapy initiation among HIV-positive patients in Shanghai,a retrospective cross-sectional study[J]. BMC Infect Dis,2017 ,17（1）:285.
[12]魏秀青,张园园,陈曦,等. 湖南省2011年艾滋病患者抗病毒治疗及时性分析[J].中国病毒病杂志,2013,3（1）:42-45.
[13]BISHOP J D,DE SHIELDS S,CUNNINGHAM T,et al. CD4 count recovery after initiation of antiretroviral therapy in patients infected with human immunodeficiency virus[J]. Am J Med Sci,2016,352（3）:239-244.
[14]GRINSZTEJN B,HOSSEINIPOUR M C,RIBAUDO H J,et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection:results from the phase 3 HPTN 052 randomised controlled trial[J]. Lancet infect Dis,2014,14（4）:281-290.
[15]王斌. 艾滋病患者抗病毒治疗前后CD4+T淋巴细胞计数变化[J]. 预防医学,2016,28（5）:483-484.
[16]TUAN L E,WRIGHT E J,SMITH D M,et al. Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy[J]. N Eng J Med,2013,368（3）:218-230.
[17]MELONI S T,CHANG C A,EISEN G,et al. Long-Term Outcomes on Antiretroviral Therapy in a Large Scale-Up Program in Nigeria. P[J]LoS One,2016,11（10）:e0164030.
[18]BEER L,BRADLEY H,MATTSON C L,et al. Trends in Racial and Ethnic Disparities in Antiretroviral Therapy Prescription and Viral Suppression in the United States,2009—2013[J]. J Acquir Immune Defic Syndr,2016,73（4）:446-453.
[19]LESKO C R,COLE S R,MILLER W C,et al. Ten-year Survival by Race/Ethnicity and Sex Among Treated,HIV-infected Adults in the United States[J]. Clin Infect Dis,2015,60（11）:1700-1707.
[20]金玫华,杨中荣,董正全,等. 湖州市艾滋病抗病毒治疗效果分析[J]. 预防医学,2016,28（10）:1019-1020. |
|
|
|
